Search

Displaying results 2461 - 2470 of 9670 in total
  1. Drug

    Isoflurophate

    go.drugbank.com/drugs/DB00677
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330) … It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically.

  2. Drug

    Goserelin

    go.drugbank.com/drugs/DB00014
    ApprovedInvestigational

    In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells.

  3. Drug

    Clonixin

    go.drugbank.com/drugs/DB09218
    Investigational

    Clonixin is a non-steroidal anti-inflammatory drug.

    Mixtures: CLONIXINATO / CICLOBENZAPRINA 125MG/5MG
  4. Drug

    Isopropamide

    go.drugbank.com/drugs/DB01625
    ApprovedVet approvedWithdrawn

    It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.

  5. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

  6. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

  7. Drug

    Abciximab

    go.drugbank.com/drugs/DB00054
    ApprovedWithdrawn

    It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

  8. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.

  9. Drug

    Temafloxacin

    go.drugbank.com/drugs/DB01405
    ApprovedWithdrawn

    It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three

  10. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    [L13988] It has also been investigated, by itself or together with [zoliflodacin], for the treatment of gonorrhea,[A203432, A203495] and was recently suggested as a possible treatment for liver-stage _ … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.